Published in J Med Chem on July 22, 2010
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
Measuring rapid hydrogen exchange in the homodimeric 36 kDa HIV-1 integrase catalytic core domain. Protein Sci (2011) 0.86
Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system. Antimicrob Agents Chemother (2011) 0.78
Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies. Bioorg Med Chem (2010) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng (1995) 19.22
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A (2000) 5.81
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell (1997) 3.98
Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med (2000) 2.40
Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem (2001) 2.31
The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci U S A (1998) 2.21
Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci U S A (2007) 1.85
NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol (2003) 1.64
Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol (2004) 1.58
A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci (2001) 1.37
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem (2002) 1.26
Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol Pharmacol (2006) 1.26
HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett (2001) 1.17
Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J Biol Chem (2005) 1.05
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J Comput Aided Mol Des (2005) 1.02
Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther (2002) 1.00
Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J Mol Biol (2007) 0.96
A capillary electrophoretic assay for ribonuclease H activity. Anal Biochem (2004) 0.88
The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. Nucleic Acids Res (2003) 0.87
Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase. Arch Biochem Biophys (2006) 0.87
A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity. Antivir Chem Chemother (2005) 0.85
Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. J Med Chem (2006) 0.84
Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain. Neurosci Res (2003) 0.80
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol (2010) 4.57
Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc Natl Acad Sci U S A (2009) 4.48
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol (2004) 4.22
Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol (2006) 4.01
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology (2004) 3.43
Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature (2004) 3.19
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol (2006) 2.85
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int (2013) 2.62
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron (2013) 2.51
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe (2012) 2.48
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol (2003) 2.28
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem (2005) 2.10
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood (2002) 1.97
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem (2003) 1.87
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85
Cotranslational response to proteotoxic stress by elongation pausing of ribosomes. Mol Cell (2013) 1.83
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem (2003) 1.81
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Prevalence of blood-borne infectious diseases in blood donors in Ghana. J Clin Microbiol (2002) 1.77
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res (2005) 1.75
CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther (2004) 1.74
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett (2003) 1.71
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) (2003) 1.70
Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem (2002) 1.69
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab (2006) 1.68
Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet (2010) 1.66
Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol (2008) 1.66
Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A (2010) 1.66
CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol (2007) 1.64
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis (2008) 1.63
A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol (2005) 1.63
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem (2002) 1.59
Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS One (2011) 1.59
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Stromal cell-derived factor 1-mediated CXCR4 signaling in rat and human cortical neural progenitor cells. J Neurosci Res (2004) 1.55
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood (2012) 1.54
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res (2003) 1.54
Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells (2007) 1.54
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res (2010) 1.53
HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem (2009) 1.53
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Bloom's syndrome helicase and Mus81 are required to induce transient double-strand DNA breaks in response to DNA replication stress. J Mol Biol (2007) 1.50
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology (2011) 1.49
Englerin A, a selective inhibitor of renal cancer cell growth, from Phyllanthus engleri. Org Lett (2009) 1.48
Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology (2010) 1.48
Endogenous gamma-H2AX-ATM-Chk2 checkpoint activation in Bloom's syndrome helicase deficient cells is related to DNA replication arrested forks. Mol Cancer Res (2007) 1.46
Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol (2004) 1.46
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A (2006) 1.45
A seed for Alzheimer amyloid in the brain. J Neurosci (2004) 1.45
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) (2006) 1.45
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44
Genome-wide depletion of replication initiation events in highly transcribed regions. Genome Res (2011) 1.44
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
Effect of admission time on mortality in an intensive care unit in Mainland China: a propensity score matching analysis. Crit Care (2013) 1.43
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem (2008) 1.43